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FOREWORD
As Director responsible for Public Health in the
European Commission, I would like to take this
opportunity to commend the publication of the
Global White Paper on Bacterial Resistance in Com-
munity Acquired Respiratory Tract Infections. The
White Paper represents a major contribution to
the ﬁght against antimicrobial resistance and I
welcome the efforts undertaken by the Interna-
tional Forum on Antibiotic Resistance in addres-
sing this complex issue from a global perspective.
Ever since the initial recognition of the signiﬁ-
cance of antibiotic resistance in human medicine,
the European Union (EU) has been proactive and
determined in tackling the problem. The EU Con-
ference ‘The Microbial Threat’ in 1998 and its
follow up in June 2001, the adoption of a Com-
munity Strategy against Antimicrobial Resistance
by the European Commission in June 2001 and the
Council Recommendation on the Prudent Use of
Antibiotics in HumanMedicine in November 2001
are indicative of the EU’s commitment to facing
this pandemic. That recommendation and a pilot
project on surveillance of antimicrobial consump-
tion in humans were launched at the ‘EU Con-
ference onAntibiotic Use in Europe’, held on 15–17
November 2001 in Brussels.
The adopted strategy, given at http://europa.eu.
int/comm/health/ph/others/antimicrob_resist/,
gives a comprehensive overview of ongoing
efforts and future activities within the Community
with regard to surveillance, prevention, research,
product development, and international co-opera-
tion with the view to stimulate further
development of programs of control. The Council
Recommendation, as an important part of that
strategy, encourages national governments to take
the necessary measures to contain the spread of
antimicrobial resistance, including a general
awareness campaign, encouraging a ‘prescription
only’ status for antibiotics and the improved mon-
itoring of antibiotic consumption.
To be truly effective, the ﬁght against antimi-
crobial resistance, like the pandemic itself, must
cross international borders. For this reason, it will
require extensive co-operation, particularly
among national and international organizations,
such as the World Health Organization (WHO),
the Centers for Disease Control and Prevention
(CDC) and learned societies.
The Global White Paper exempliﬁes such co-
operation in bringing together experts from across
the globe. This unique assembly of interested par-
ties has generated a paper which critically evalu-
ates existing knowledge and strategies, addresses
omissions, and identiﬁes tested interventions that
could play a pivotal role in future strategies to
combat antimicrobial resistance. I am convinced
that it is only when we co-operate and pool our
knowledge and experience in such a manner, that
we will be able to combat the threat of antimicro-
bial resistance and preserve the effectiveness of
antibiotics for generations to come.
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